Concepts (154)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Methicillin-Resistant Staphylococcus aureus | 5 | 2023 | 56 | 2.450 |
Why?
|
| Staphylococcal Infections | 6 | 2023 | 58 | 2.280 |
Why?
|
| Rotavirus Vaccines | 6 | 2016 | 12 | 1.910 |
Why?
|
| Community-Acquired Infections | 4 | 2023 | 22 | 1.830 |
Why?
|
| Rotavirus Infections | 5 | 2016 | 15 | 1.770 |
Why?
|
| Gastroenteritis | 4 | 2016 | 17 | 1.650 |
Why?
|
| Carrier State | 2 | 2017 | 29 | 1.010 |
Why?
|
| Masks | 1 | 2023 | 11 | 0.890 |
Why?
|
| Anti-Bacterial Agents | 4 | 2023 | 352 | 0.880 |
Why?
|
| Georgia | 9 | 2023 | 174 | 0.870 |
Why?
|
| Rotavirus | 3 | 2016 | 11 | 0.730 |
Why?
|
| Pediatrics | 2 | 2013 | 68 | 0.690 |
Why?
|
| Staphylococcus aureus | 5 | 2023 | 75 | 0.690 |
Why?
|
| Child | 14 | 2023 | 3131 | 0.690 |
Why?
|
| Infant | 11 | 2021 | 1046 | 0.690 |
Why?
|
| Electronic Health Records | 1 | 2019 | 66 | 0.640 |
Why?
|
| Staphylococcal Skin Infections | 2 | 2017 | 9 | 0.620 |
Why?
|
| Soft Tissue Infections | 1 | 2017 | 6 | 0.590 |
Why?
|
| Child, Preschool | 10 | 2023 | 1418 | 0.550 |
Why?
|
| Vaccination | 2 | 2016 | 288 | 0.520 |
Why?
|
| Humans | 30 | 2023 | 37093 | 0.440 |
Why?
|
| Health Personnel | 2 | 2013 | 228 | 0.430 |
Why?
|
| Ambulatory Care | 1 | 2013 | 75 | 0.420 |
Why?
|
| Health Status Disparities | 3 | 2023 | 642 | 0.420 |
Why?
|
| Lead Poisoning | 2 | 2023 | 26 | 0.410 |
Why?
|
| Information Systems | 1 | 2011 | 15 | 0.410 |
Why?
|
| Medicaid | 3 | 2020 | 109 | 0.400 |
Why?
|
| Lead | 2 | 2023 | 93 | 0.380 |
Why?
|
| Case-Control Studies | 5 | 2017 | 1130 | 0.350 |
Why?
|
| Retrospective Studies | 5 | 2023 | 2026 | 0.350 |
Why?
|
| Methicillin Resistance | 2 | 2007 | 11 | 0.330 |
Why?
|
| Emergency Service, Hospital | 4 | 2020 | 208 | 0.290 |
Why?
|
| Abscess | 2 | 2017 | 7 | 0.290 |
Why?
|
| Infant, Newborn | 3 | 2019 | 894 | 0.290 |
Why?
|
| Female | 14 | 2023 | 20969 | 0.280 |
Why?
|
| Male | 14 | 2023 | 20025 | 0.280 |
Why?
|
| Feces | 2 | 2016 | 111 | 0.270 |
Why?
|
| Methicillin | 1 | 2023 | 4 | 0.230 |
Why?
|
| United States | 6 | 2023 | 4223 | 0.220 |
Why?
|
| Prevalence | 4 | 2017 | 1455 | 0.210 |
Why?
|
| Interleukin-10 | 1 | 2021 | 75 | 0.200 |
Why?
|
| Schools | 1 | 2023 | 260 | 0.190 |
Why?
|
| Asthma | 2 | 2016 | 380 | 0.190 |
Why?
|
| AIDS Serodiagnosis | 1 | 2000 | 25 | 0.180 |
Why?
|
| Specialization | 1 | 2020 | 21 | 0.180 |
Why?
|
| Mass Screening | 2 | 2021 | 462 | 0.170 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2000 | 103 | 0.160 |
Why?
|
| Chlamydia Infections | 1 | 2020 | 196 | 0.160 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 1998 | 12 | 0.160 |
Why?
|
| Circadian Rhythm | 1 | 2020 | 225 | 0.160 |
Why?
|
| Herpesvirus 1, Human | 1 | 1998 | 54 | 0.150 |
Why?
|
| Vulnerable Populations | 1 | 2019 | 140 | 0.150 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2017 | 4 | 0.150 |
Why?
|
| Clindamycin | 1 | 2017 | 13 | 0.150 |
Why?
|
| Population Surveillance | 1 | 2019 | 238 | 0.150 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2017 | 201 | 0.150 |
Why?
|
| Virus Shedding | 1 | 2016 | 8 | 0.150 |
Why?
|
| Circovirus | 1 | 2016 | 9 | 0.140 |
Why?
|
| Mediastinal Diseases | 1 | 1996 | 1 | 0.140 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2016 | 31 | 0.140 |
Why?
|
| Incidence | 1 | 2019 | 922 | 0.140 |
Why?
|
| Residence Characteristics | 1 | 2019 | 322 | 0.130 |
Why?
|
| Cross Protection | 1 | 2015 | 4 | 0.130 |
Why?
|
| RNA, Viral | 1 | 2016 | 301 | 0.130 |
Why?
|
| DNA, Viral | 1 | 2016 | 304 | 0.130 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 2 | 2013 | 27 | 0.120 |
Why?
|
| Vaccines, Combined | 2 | 2023 | 11 | 0.120 |
Why?
|
| Diarrhea, Infantile | 1 | 2013 | 5 | 0.110 |
Why?
|
| Risk Factors | 3 | 2017 | 3562 | 0.100 |
Why?
|
| Connecticut | 1 | 2011 | 14 | 0.100 |
Why?
|
| Minnesota | 1 | 2011 | 40 | 0.100 |
Why?
|
| Vaccines, Attenuated | 3 | 2016 | 72 | 0.100 |
Why?
|
| Adolescent | 2 | 2019 | 5363 | 0.090 |
Why?
|
| Neurons | 1 | 1998 | 1175 | 0.090 |
Why?
|
| Genotype | 1 | 2013 | 730 | 0.090 |
Why?
|
| HIV Infections | 1 | 2000 | 2303 | 0.070 |
Why?
|
| Small-Area Analysis | 2 | 2016 | 8 | 0.070 |
Why?
|
| Pregnancy | 2 | 2020 | 1549 | 0.060 |
Why?
|
| Adult | 4 | 2023 | 11712 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2019 | 1378 | 0.060 |
Why?
|
| Clinical Protocols | 1 | 2023 | 36 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 610 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 2721 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2023 | 109 | 0.050 |
Why?
|
| Linear Models | 1 | 2023 | 275 | 0.050 |
Why?
|
| Acute-Phase Proteins | 1 | 2021 | 14 | 0.050 |
Why?
|
| Leukocyte Count | 1 | 2021 | 77 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2023 | 262 | 0.050 |
Why?
|
| Laboratories | 1 | 2021 | 35 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 1067 | 0.050 |
Why?
|
| Pregnancy, Ectopic | 1 | 2020 | 14 | 0.050 |
Why?
|
| Photoperiod | 1 | 2020 | 26 | 0.050 |
Why?
|
| Pelvic Inflammatory Disease | 1 | 2020 | 19 | 0.050 |
Why?
|
| Chicago | 1 | 2000 | 30 | 0.050 |
Why?
|
| Chlamydia | 1 | 2020 | 42 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2021 | 211 | 0.050 |
Why?
|
| Lipopolysaccharides | 1 | 2021 | 220 | 0.050 |
Why?
|
| Probability | 1 | 2000 | 78 | 0.040 |
Why?
|
| Poverty | 1 | 2023 | 348 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2000 | 47 | 0.040 |
Why?
|
| Chlamydia muridarum | 1 | 2020 | 104 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2021 | 305 | 0.040 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2000 | 72 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2000 | 144 | 0.040 |
Why?
|
| Gas Gangrene | 1 | 1999 | 1 | 0.040 |
Why?
|
| Clostridium perfringens | 1 | 1999 | 3 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2023 | 1207 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2021 | 216 | 0.040 |
Why?
|
| Texas | 1 | 2020 | 324 | 0.040 |
Why?
|
| Chondroitin ABC Lyase | 1 | 1998 | 2 | 0.040 |
Why?
|
| Polysaccharide-Lyases | 1 | 1998 | 10 | 0.040 |
Why?
|
| Galactosides | 1 | 1998 | 11 | 0.040 |
Why?
|
| Heparin | 1 | 1998 | 35 | 0.040 |
Why?
|
| Chick Embryo | 1 | 1998 | 74 | 0.040 |
Why?
|
| Vero Cells | 1 | 1998 | 93 | 0.040 |
Why?
|
| Cytokines | 1 | 2021 | 602 | 0.040 |
Why?
|
| Urban Population | 1 | 2000 | 333 | 0.040 |
Why?
|
| Epithelium | 1 | 1998 | 79 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 12 | 0.040 |
Why?
|
| Drainage | 1 | 2017 | 11 | 0.040 |
Why?
|
| Viral Envelope Proteins | 1 | 1998 | 82 | 0.040 |
Why?
|
| Registries | 1 | 2019 | 335 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 148 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2020 | 294 | 0.040 |
Why?
|
| Inflammation | 1 | 2021 | 618 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 1998 | 502 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2017 | 286 | 0.040 |
Why?
|
| Indoles | 1 | 1998 | 158 | 0.040 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2016 | 19 | 0.030 |
Why?
|
| Fibroblasts | 1 | 1998 | 272 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2000 | 404 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 225 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2016 | 215 | 0.030 |
Why?
|
| Air Pollution | 1 | 2016 | 60 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 1609 | 0.030 |
Why?
|
| Astrocytes | 1 | 1998 | 255 | 0.030 |
Why?
|
| Diarrhea | 1 | 2015 | 89 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1996 | 214 | 0.030 |
Why?
|
| Utilization Review | 1 | 2013 | 14 | 0.030 |
Why?
|
| Immunization, Secondary | 1 | 2013 | 8 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2013 | 20 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2013 | 149 | 0.030 |
Why?
|
| Patient Admission | 1 | 2013 | 41 | 0.030 |
Why?
|
| Animals | 2 | 2020 | 15081 | 0.030 |
Why?
|
| Time Factors | 1 | 2016 | 1742 | 0.030 |
Why?
|
| Mice | 1 | 2020 | 5913 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2013 | 1369 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 1999 | 40 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 1999 | 22 | 0.010 |
Why?
|
| Genes, Bacterial | 1 | 1998 | 90 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 1998 | 186 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1998 | 448 | 0.010 |
Why?
|
| Pain | 1 | 1999 | 251 | 0.010 |
Why?
|
| Hospitalization | 1 | 1998 | 388 | 0.010 |
Why?
|